Stock Price Movement and Market Context
On 25 Nov 2025, Shree Ganesh Biotech India’s stock price settled at Rs.0.62, representing a day change of -1.54%. This performance notably underperformed its sector, which saw a gain of 3.8% in the Agriculture segment, while the Pharmaceuticals & Biotechnology sector itself faced headwinds. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In contrast, the broader market displayed resilience, with the Sensex opening higher at 85,008.93 points and closing near 84,957.75 points, just 0.99% shy of its 52-week high of 85,801.70. The Sensex’s 50-day moving average remains above its 200-day moving average, indicating a generally bullish trend in the wider market. Mid-cap stocks led gains with the BSE Mid Cap index rising by 0.16% on the day.
Financial Performance Highlights
Shree Ganesh Biotech India’s financial results over the past year have shown considerable strain. The company’s net sales for the nine months ending September 2025 stood at Rs.5.16 crores, reflecting a contraction of 44.64% compared to the previous period. Correspondingly, the profit after tax (PAT) recorded a loss of Rs.0.61 crores, also down by 44.64% year-on-year.
The company’s return on equity (ROE) averaged 2.62%, indicating limited profitability relative to shareholders’ funds. Additionally, the EBIT to interest coverage ratio averaged 0.91, suggesting challenges in servicing debt obligations effectively. The debtors turnover ratio for the half year was recorded at 0.00 times, highlighting potential issues in receivables management.
Perfect timing to enter! This Small Cap from IT - Software just turned profitable with growth momentum clearly building up. Get in before the broader market notices!
- - New profitability achieved
- - Growth momentum building
- - Under-the-radar entry
Comparative Performance and Valuation
Over the last twelve months, Shree Ganesh Biotech India’s stock has declined by 38.46%, contrasting with the Sensex’s positive return of 6.05% during the same period. The stock’s valuation appears elevated relative to its historical averages, with profitability metrics showing a fall of 86.6% in profits over the past year. This divergence underscores the challenges faced by the company amid a broader market environment that has remained relatively stable.
The stock’s trading below all major moving averages further emphasises the subdued investor sentiment and the absence of upward price momentum. The company’s shareholder base is predominantly non-institutional, which may influence trading patterns and liquidity considerations.
Holding Shree Ganesh Biotech India from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Sector and Industry Considerations
Shree Ganesh Biotech India operates within the Pharmaceuticals & Biotechnology sector, which has experienced mixed performance in recent sessions. While the Agriculture sector posted gains of 3.8% on the day, the Pharmaceuticals & Biotechnology sector has faced headwinds, reflected in the underperformance of Shree Ganesh Biotech India’s stock relative to sector peers.
The company’s current market capitalisation grade is noted as 4, indicating a mid-range market cap within its sector. Despite the broader market’s positive trend, the stock’s performance remains subdued, influenced by its financial metrics and valuation concerns.
Summary of Key Financial Metrics
To summarise, Shree Ganesh Biotech India’s recent financial and market data reveal:
- New 52-week and all-time low price of Rs.0.62
- Net sales for nine months at Rs.5.16 crores, down 44.64%
- Profit after tax loss of Rs.0.61 crores, down 44.64%
- Return on equity averaging 2.62%
- EBIT to interest coverage ratio averaging 0.91
- Debtors turnover ratio at 0.00 times for half year
- Stock trading below all major moving averages
- One-year stock return of -38.46% versus Sensex’s 6.05%
These figures collectively illustrate the pressures faced by Shree Ganesh Biotech India in maintaining profitability and market valuation amid a challenging sector environment.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
